Summary
91.07
0.29
(0.32%)
06/05/2026
Abbott Laboratories (ABT)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| 0.32 | 3.75 | 4.47 | -17.47 | -26.37 | -30.62 | -9.04 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | B+ |
| Recommended Rating | Neutral |
| DCF | Buy |
| ROE | Buy |
| ROA | Strong Buy |
| Debt/Equity | Strong Sell |
| P/E | Sell |
| P/B | Sell |
Earnings
| Trading Data | ||
| Close | 91.07 | |
| Open | 91.75 | |
| High | 92.73 | |
| Low | 90.96 | |
| Volume | 11,885,478 | |
| Change | 0.29 | |
| Change % | 0.32 | |
| Avg Volume (20 Days) | 11,971,953 | |
| Volume/Avg Volume (20 Days) Ratio | 0.99 | |
| 52 Week Range | 81.97 - 136.28 | |
| Price vs 52 Week High | -33.17% | |
| Price vs 52 Week Low | 11.10% | |
| Range | -0.74 | |
| Gap Up/Down | 0.27 | |
Profitibility | ||
| Market Capitalization (Mln) | 218,327 | |
| Revenue per share | 25.8358 | |
| Net Income per share | 3.5925 | |
| Dividend Yield | 0.0268 | |
| Dividend Share | 244.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | 25.3498 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
06/06 10:00 EST - gurufocus.com
New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis PR Newswire A
New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis PR Newswire A
06/04 11:02 EST - zacks.com
Abbott Addresses a Major Diabetes Care Gap With Tech Innovation
ABT wins the CE Mark for Libre Duo sensors that track glucose and ketones every minute, aiming to spot DKA risks earlier and reduce routine testing.
Abbott Addresses a Major Diabetes Care Gap With Tech Innovation
ABT wins the CE Mark for Libre Duo sensors that track glucose and ketones every minute, aiming to spot DKA risks earlier and reduce routine testing.
06/02 07:04 EST - gurufocus.com
ABT DCF Analysis: Intrinsic Value $93 vs Price $88
On June 02, 2026, we take a closer look at the DCF analysis for Abbott Laboratories (ABT). The stock has experienced notable price performance, with a year-to-d
ABT DCF Analysis: Intrinsic Value $93 vs Price $88
On June 02, 2026, we take a closer look at the DCF analysis for Abbott Laboratories (ABT). The stock has experienced notable price performance, with a year-to-d
06/02 04:15 EST - fool.com
3 Beaten-Down Stocks to Buy and Hold Forever
Don't wait too long to buy the dip on these stocks.
3 Beaten-Down Stocks to Buy and Hold Forever
Don't wait too long to buy the dip on these stocks.
06/01 10:56 EST - zacks.com
Abbott's CE Mark Win for Libre Duo Systems May Lift Its Stock
ABT wins CE Mark for Libre Duo systems, the first dual glucose-ketone sensors, enabling real-time monitoring as European rollout begins later this year.
Abbott's CE Mark Win for Libre Duo Systems May Lift Its Stock
ABT wins CE Mark for Libre Duo systems, the first dual glucose-ketone sensors, enabling real-time monitoring as European rollout begins later this year.
05/29 10:16 EST - zacks.com
BSX vs. ABT: Which Medical Stock Has More Upside Potential?
Boston Scientific and Abbott both posted solid quarterly growth, but analysts see stronger upside for Boston Scientific despite mounting operational pressures.
BSX vs. ABT: Which Medical Stock Has More Upside Potential?
Boston Scientific and Abbott both posted solid quarterly growth, but analysts see stronger upside for Boston Scientific despite mounting operational pressures.
05/29 10:01 EST - zacks.com
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.
05/28 10:31 EST - zacks.com
Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
05/27 18:51 EST - zacks.com
Abbott (ABT) Stock Falls Amid Market Uptick: What Investors Need to Know
Abbott (ABT) concluded the recent trading session at $85.68, signifying a -1.14% move from its prior day's close.
Abbott (ABT) Stock Falls Amid Market Uptick: What Investors Need to Know
Abbott (ABT) concluded the recent trading session at $85.68, signifying a -1.14% move from its prior day's close.
05/27 09:53 EST - zacks.com
How Abbott's Diagnostics Unit Is Shaping Up Through the Rest of 2026
ABT's Diagnostics unit witnesses mixed Q1 results as Core Lab growth offsets China weakness and softer respiratory testing demand.
How Abbott's Diagnostics Unit Is Shaping Up Through the Rest of 2026
ABT's Diagnostics unit witnesses mixed Q1 results as Core Lab growth offsets China weakness and softer respiratory testing demand.
05/27 09:00 EST - prnewswire.com
Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
First-of-its-kind biowearables combine continuous glucose and ketone monitoring in a single sensor to support both daily diabetes management and help detect rising ketone levels that can lead to diabetic ketoacidosis, a serious health condition for people with diabetes Integrates with the Libre...
Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
First-of-its-kind biowearables combine continuous glucose and ketone monitoring in a single sensor to support both daily diabetes management and help detect rising ketone levels that can lead to diabetic ketoacidosis, a serious health condition for people with diabetes Integrates with the Libre...
05/27 07:01 EST - prnewswire.com
ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
Cologuard® and Cologuard Plus® reaffirmed as preferred options for noninvasive colorectal cancer (CRC) screening in updated American Cancer Society guideline Abbott to offer only CRC screening portfolio aligned to new ACS recommendations combining preferred stool-based plus additional blood-based...
ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
Cologuard® and Cologuard Plus® reaffirmed as preferred options for noninvasive colorectal cancer (CRC) screening in updated American Cancer Society guideline Abbott to offer only CRC screening portfolio aligned to new ACS recommendations combining preferred stool-based plus additional blood-based...
05/26 09:00 EST - prnewswire.com
Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
Data highlight how screening and diagnostics enable earlier detection, more precise treatment decisions, and improved patient outcomes from risk to remission New MRD data from the PARTNER study demonstrate enhanced sensitivity in early triple-negative breast cancer Early MCED prospective data show...
Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
Data highlight how screening and diagnostics enable earlier detection, more precise treatment decisions, and improved patient outcomes from risk to remission New MRD data from the PARTNER study demonstrate enhanced sensitivity in early triple-negative breast cancer Early MCED prospective data show...
05/22 21:15 EST - fool.com
The Smartest Growth Stocks to Invest $10,000 in As Investors Rotate Out of Tech
When investors take a risk-off attitude, stocks with attractive, growing dividends are often their safe-haven option.
The Smartest Growth Stocks to Invest $10,000 in As Investors Rotate Out of Tech
When investors take a risk-off attitude, stocks with attractive, growing dividends are often their safe-haven option.
05/21 02:30 EST - fool.com
3 Stocks to Buy if You Think the Economy Is Heading for a Recession
They have increased their payouts for a combined 171 years straight.
3 Stocks to Buy if You Think the Economy Is Heading for a Recession
They have increased their payouts for a combined 171 years straight.
05/20 09:41 EST - zacks.com
Abbott's Biosimilar Push to Help Sustain EPD Growth Momentum
ABT's EPD unit posts 9% Q1 sales growth as biosimilars and emerging market demand support its long-term expansion plans.
Abbott's Biosimilar Push to Help Sustain EPD Growth Momentum
ABT's EPD unit posts 9% Q1 sales growth as biosimilars and emerging market demand support its long-term expansion plans.
05/19 16:01 EST - zacks.com
Silver Economy Investing: Why the Healthcare Giants Are in Focus
Healthcare giants like Eli Lilly, Tandem Diabetes, Intuitive Surgical and ResMed are tapping aging-driven demand in obesity, surgery and sleep care.
Silver Economy Investing: Why the Healthcare Giants Are in Focus
Healthcare giants like Eli Lilly, Tandem Diabetes, Intuitive Surgical and ResMed are tapping aging-driven demand in obesity, surgery and sleep care.
05/19 07:30 EST - seekingalpha.com
The Dip That Keeps On Dipping: 2 Strong Buy Stocks Near 52-Week Lows With 50%+ Upside Potential
Build-A-Bear Workshop and Abbott Laboratories are compelling dividend stocks, each trading near lows with yields close to 3%. BBW offers a debt-free balance sheet, aggressive share repurchases, and international expansion, positioning for 9.3% earnings CAGR and over 70% upside to its $62 target....
The Dip That Keeps On Dipping: 2 Strong Buy Stocks Near 52-Week Lows With 50%+ Upside Potential
Build-A-Bear Workshop and Abbott Laboratories are compelling dividend stocks, each trading near lows with yields close to 3%. BBW offers a debt-free balance sheet, aggressive share repurchases, and international expansion, positioning for 9.3% earnings CAGR and over 70% upside to its $62 target....
Market News
×
Loading news…